Glucagen Hypokit

Glucagen Hypokit is a prescription product that contains the hormone glucagon as its active ingredient. It is supplied in a ready‑to‑use kit for intramuscular or subcutaneous injection, though specific strength and dosage form are not disclosed. Marketed in the European Union, Glucagen Hypokit is classified under ATC code H01BA01 and is intended for rapid emergency treatment of severe hypoglycemia by patients or caregivers or healthcare professionals.

Glucagen Hypokit is indicated for the immediate management of severe hypoglycemia when oral glucose is not feasible.

- Acute treatment of insulin‑induced hypoglycemia in diabetic patients. - Rescue therapy for hypoglycemia unawareness or prolonged low blood glucose. - Emergency use in settings without immediate medical supervision. - Administration by trained caregivers, family members, or healthcare personnel. - May be employed in hospital, outpatient, or home environments for rapid glucose elevation.

The safety profile of glucagon injection reflects its pharmacologic action on glucose metabolism and the injection site.

Common: - Nausea or vomiting. - Abdominal discomfort or pain. - Flushing or warmth. - Headache. - Injection‑site pain or bruising. - Mild tremor.

Serious: - Severe allergic reaction (anaphylaxis). - Marked hyperglycemia. - Cardiovascular events such as tachycardia or arrhythmia. - Seizures (rare). - Significant hypokalemia.

Before using Glucagen Hypokit, certain precautions should be considered to ensure safe and effective treatment.

- Verify hypoglycemia severity; use only when blood glucose is critically low. - Ensure proper reconstitution and dosage according to the kit instructions. - Do not administer to patients with known hypersensitivity to glucagon or kit components. - Caution in patients with pheochromocytoma, adrenal insufficiency, or recent myocardial infarction. - Monitor blood glucose after administration and repeat dose if necessary. - Store at controlled room temperature, protect from light and moisture. - Keep out of reach of children.

Glucagon may interact with other medications or conditions that affect glucose levels or cardiovascular function.

Avoid: - Concurrent use of beta‑blockers may blunt the glycemic response. - Do not combine with insulin analogs that have prolonged action without monitoring. - Avoid administration in patients receiving catecholamine excess (e.g., pheochromocytoma) without supervision.

Use with caution: - Caution when used with oral hypoglycemic agents; monitor for recurrent hypoglycemia. - Use carefully in patients on digoxin or other cardiac glycosides due to potential arrhythmias. - Consider dose adjustment in renal or hepatic impairment. - Observe for interactions with drugs that affect gastric motility.